VivoSeq
Hematology

AL Amyloidosis

42

Pipeline Programs↗

24

Active Trials↗

22

Companies Involved↗

AL amyloidosis is a moderately active landscape with 42 programs across 22 companies. The most active players are Sorrento Therapeutics, Inc., Gracell Biotechnologies (Shanghai) Co., Ltd., Regeneron. 4 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

15/100

Mech. Concentration

13/100

Completion Rate

63/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sorrento Therapeutics, Inc.

1 program

Phase 1G

Gracell Biotechnologies (Shanghai) Co., Ltd.

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1N

Nanjing IASO Biotechnology Co., Ltd.

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical7

Venetoclax

AbbVie

Florbetaben

Life Molecular Imaging GmbH

Dara-SC

Johnson & Johnson

Anti-CD38 Monoclonal Antibody

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Dara IV

Johnson & Johnson

Phase 14

Elranatamab

Pfizer

Linvoseltamab

Regeneron

STI-6129

Sorrento Therapeutics, Inc.

GC012F

Gracell Biotechnologies (Shanghai) Co., Ltd.

Phase 215

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Ixazomib

Takeda

Teclistamab

Johnson & Johnson

Pomalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 312

Daratumumab

Johnson & Johnson

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Melphalan

Apotex Inc.

Dexamethasone

Aspen Global Incorporated

Filgrastim

Eastern Cooperative Oncology Group

Approved4

Tafamidis

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Cyclophosphamide

Baxter Healthcare Corporation

Thalidomide

Bristol-Myers Squibb

Amiodarone

Wyeth-Lederle Vaccines

Analysis

Modality Breakdown

74%

Small molecule

34 of 46 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody715%Cell therapy37%Antibody–drug conjugate12%Protein / enzyme12%

Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 89% of 54 pipeline programs.

Analysis

Trial Status

56

clinical trials

Completed19 · 34%
Recruiting15 · 27%
Terminated9 · 16%
Active, not recruiting5 · 9%
Not yet recruiting4 · 7%
Unknown status2 · 4%
Other2 · 4%

Clinical Trials

Trial Activity

56 trials

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Recruiting·FFondazione IRCCS Policlinico San Matteo di Pavia·N/A·NCT04392960·69 enrolled
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
Recruiting·YYongyong MA·N/A·NCT06455748·20 enrolled
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Recruiting·IIntergroupe Francophone du Myelome·Phase 2·NCT05066607·46 enrolled
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Recruiting·PPeking University People's Hospital·N/A·NCT06699394·20 enrolled
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Recruiting·LLife Molecular Imaging GmbH·Phase 3·NCT05184088·200 enrolled
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07079423·35 enrolled
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Recruiting·SWOG Cancer Research Network·Phase 3·NCT06022939·338 enrolled
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Recruiting·GGracell Biotechnologies (Shanghai) Co., Ltd.·Phase 1·NCT07250269·9 enrolled
Rapid dFLC Response Predict CHR in AL Amyloidosis
Recruiting·PPeking University People's Hospital·N/A·NCT06627309·50 enrolled
Teclistamab in Previously Treated AL Amyloidosis
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06935162·30 enrolled
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Recruiting·—·Phase 2·NCT06342466·40 enrolled
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Recruiting·—·Phase 1/2·NCT06569147·49 enrolled
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT05145816·37 enrolled
A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.
Recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT07081646·91 enrolled
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT06420167·20 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)